REMS Certification for Pharmacies and Prescribers
How do pharmacies and prescribers get REMS certified?
Under FDA REMS programs, certification is set separately for each drug's REMS, not by a single national licence. Prescribers usually certify by reading the Prescribing Information, sometimes completing training and a knowledge assessment, and sending a Prescriber Enrollment Form to that drug's REMS. Pharmacies certify through a designated authorized representative, who enrolls the pharmacy, trains staff and sets up verification procedures. The steps below are taken from the program pages on REMS@FDA.
Prescribers
The core step in every program here is the same. The prescriber reviews the drug's Prescribing Information and enrolls by "completing and submitting the Prescriber Enrollment Form to the REMS".
- Enrollment form only: Filspari [1], bosentan [2], Siliq [3] and Palforzia [4].
- Training and a knowledge assessment as well:
- Patient enrollment: in many programs the prescriber also enrolls each patient with a Patient Enrollment Form (for example Filspari, bosentan and TIRF) [1][7].
- Recertification: some programs require it.
- Prescribers who dispense: under Siliq, a prescriber who dispenses completes the certified dispenser section of the Prescriber Enrollment Form [3].
Pharmacies
The pharmacy, not each pharmacist, is certified. The pattern is consistent across programs:
- Designate an authorized representative "to carry out the certification process and oversee implementation and compliance with the REMS on behalf of the pharmacy" [1].
- Review the program's guide or education material. The authorized representative reads the Pharmacy Guide or equivalent. In some programs they must also pass a knowledge assessment (TIRF Pharmacy Knowledge Assessment [7]).
- Enroll the pharmacy with the right form. Forms differ by program:
- Train all relevant dispensing staff and keep training records [2][6].
- Set up verification procedures and check before dispensing. Many programs require the pharmacy to "obtain authorization to dispense each prescription" from the REMS. What it confirms depends on the drug:
- Keep certification current:
Healthcare settings and distributors. Where the drug has to be given on site (Spravato, Aveed, Palforzia, Zyprexa Relprevv), the clinic or hospital is certified through its own authorized representative. These programs also add site conditions:
- a prescriber on site (Spravato) [11];
- emergency equipment and trained staff to manage POME (pulmonary oil microembolism) and anaphylaxis (Aveed) [8].
Wholesalers-distributors are not certified, but they must ship only to certified pharmacies or settings [10].
Where to get the forms. Each program's REMS@FDA page links the current enrollment forms and guides. For example, Filspari's Outpatient Pharmacy Enrollment Form is published on accessdata.fda.gov [1]. Submission is to the sponsor's REMS program, not to the FDA. Brixadi, for instance, dropped the option to mail its enrollment form in August 2025 [10].
Approach: I read the requirements in 11 currently approved REMS programs with elements to assure safe use, as published on REMS@FDA. I did not check the statutory REMS provisions or the FDA's general REMS guidance. If you name a specific drug, I can give its exact certification steps and current forms.
What requirements apply after enrollment?
Once enrolled, prescribers and dispensers take on ongoing duties under each REMS. These fall into four groups: patient monitoring and counseling on a fixed schedule, a check before every dispense, adverse event reporting to the REMS, and record-keeping with audits. Some programs also require periodic recertification, and the pharmacy or setting must re-enroll whenever its authorized representative changes. The details below come from the same 11 programs on REMS@FDA.
1. Prescribers: monitoring, counseling and reporting during treatment
- Scheduled monitoring:
- Repeat counseling:
- Adverse event reporting to the REMS "at all times":
- Filspari and bosentan: events suggesting liver injury [1][2].
- Elrexfio: serious CRS and neurologic toxicity, including ICANS [6].
- Palforzia: anaphylaxis, including suspected cases managed as anaphylaxis, on the Anaphylaxis Adverse Event Reporting Form [4].
- Zyprexa Relprevv: PDSS events "within 1 day" [5].
- Miudella: events suggesting improper insertion, reported to Organon LLC [9].
- Status changes: Siliq and Palforzia require reports of treatment discontinuation or transfer of care [3][4]. TIRF requires a Patient Discontinuation Form [7].
2. Pharmacies and settings: checks for each dispense or administration
- Authorization before each prescription: the pharmacy contacts the REMS to confirm the program's conditions are met.
- Bosentan: patient enrolled, prescriber and pharmacy certified, counseling done, and liver testing complete or the refill authorized by the prescriber [2].
- Siliq: prescriber certified and patient enrolled [3].
- Elrexfio: prescriber certified [6].
- TIRF: patient opioid tolerant [7].
- Zyprexa Relprevv: healthcare setting certified. The pharmacy also reports the date of dispensing [5].
- Filspari outpatient pharmacies: counsel at the first dispense and then every 3 months, document and submit that counseling, and verify liver testing or a prescriber-authorized refill [1].
- Post-dose observation in the setting:
- Zyprexa Relprevv: continuous monitoring for at least 3 hours [5].
- Spravato: at least 2 hours, and the Patient Monitoring Form is due within 7 calendar days of each administration [11].
- Aveed: 30 minutes after each injection [8].
- Palforzia: at least 60 minutes for the Initial Dose Escalation and the first dose of each new Up-Dosing level. Before home-use Daily Dose Packs are dispensed, someone must confirm the patient tolerated that dose [4].
3. Distribution limits, records and audits (dispensers)
- No onward supply: pharmacies "Not distribute, transfer, loan, or sell" the drug. Some programs allow it only to certified dispensers (Filspari, bosentan, Elrexfio, Spravato); others ban it outright (Palforzia, Zyprexa Relprevv, TIRF, Brixadi) [1][4][10].
- Records: almost every program requires three kinds:
- Audits: dispensers must "comply with audits" by the sponsor or a third party acting for it. Examples are Travere, Pfizer, Janssen and Endo [1][8].
- TIRF applicants must audit all certified outpatient pharmacies each year, up to a maximum of 400, that received at least one TIRF shipment in the past 12 months [7].
4. Keeping certification current
- New authorized representative: every program requires the pharmacy or setting to re-enroll when its representative changes.
- TIRF: the new representative must also review the Pharmacy Education and pass the knowledge assessment [7].
- Recertification on a fixed schedule:
- Inactivity: a Miudella provider who has not inserted it for any two-year period must review the Insertion Training Program again. The healthcare setting must track its providers so it can identify them [9].
- Wholesalers-distributors: they keep and submit distribution records. Elrexfio requires these "at least on a monthly basis" [6].
Approach: I read the post-enrollment requirements on the REMS@FDA pages for the same 11 programs with elements to assure safe use. Other REMS programs and the statutory REMS provisions were not reviewed here.